BRPI0417996A - agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular - Google Patents
agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macularInfo
- Publication number
- BRPI0417996A BRPI0417996A BRPI0417996-0A BRPI0417996A BRPI0417996A BR PI0417996 A BRPI0417996 A BR PI0417996A BR PI0417996 A BRPI0417996 A BR PI0417996A BR PI0417996 A BRPI0417996 A BR PI0417996A
- Authority
- BR
- Brazil
- Prior art keywords
- agents
- macular degeneration
- diabetic retinopathy
- formation
- treating diabetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"AGENTES PARA TRATAMENTO DE RETINOPATIA DIABéTICA E FORMAçãO DE GáNGLIOS EM DEGENERAçãO MACULAR". Agentes que estimulam a translocação nuclear de proteína Nrf2 e os aumentos subseqüentes em produtos genéticos que desintoxicam e eliminam metabólitos citotóxicos são providos em um método para tratar retinopatia diabética ou formação de drusas em degeneração macular relacionada com a idade. Os agentes estruturalmente diversos que atuam sobre a via Nrf2/ARE induzem a expressão de enzimas e proteínas que têm propriedades citoprotetoras quimicamente versáteis e são uma defesa contra metabólitos e xenobióticos tóxicos. Agentes incluem certos eletrófilos e oxidantes tais como um aceptor de Adição Michael, difenol, tiocarbamato, quinona, 1,2-ditiol-3-tiona, hidroxianisoóis butilados, flavonóide ou outra genisteina, um isotiocianato, 3,5-di-terc-butil-4-hidroxitolueno, etoxiquina, uma coumarina, combinações dos mesmos, ou um derivado ou análogo farmacologicamente ativo dos mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53181103P | 2003-12-22 | 2003-12-22 | |
PCT/US2004/042562 WO2005063249A1 (en) | 2003-12-22 | 2004-12-17 | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0417996A true BRPI0417996A (pt) | 2007-04-27 |
Family
ID=34738705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0417996-0A BRPI0417996A (pt) | 2003-12-22 | 2004-12-17 | agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular |
Country Status (9)
Country | Link |
---|---|
US (2) | US20050137147A1 (pt) |
EP (1) | EP1696926A1 (pt) |
JP (1) | JP2007515422A (pt) |
AU (1) | AU2004308911B2 (pt) |
BR (1) | BRPI0417996A (pt) |
CA (1) | CA2548146A1 (pt) |
MX (1) | MXPA06006862A (pt) |
WO (1) | WO2005063249A1 (pt) |
ZA (1) | ZA200605378B (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200604862B (en) * | 2003-12-22 | 2007-10-31 | Alcon Inc | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
WO2005102345A1 (en) * | 2004-03-30 | 2005-11-03 | Alcon, Inc. | Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
WO2006030907A1 (ja) * | 2004-09-16 | 2006-03-23 | Redox Bioscience Inc. | 網膜保護剤 |
WO2007005879A2 (en) * | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
FR2902326B1 (fr) * | 2006-06-20 | 2008-12-05 | Oreal | Utilisation de la coumarine, de butylated hydroxyanisole et d'ethoxyquine pour le traitement de la canitie |
WO2008016095A1 (fr) * | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE |
WO2008111497A1 (ja) * | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
US20090324740A1 (en) * | 2008-06-13 | 2009-12-31 | Albritton Iv Ford D | Novel nasal spray |
CA2747418A1 (en) * | 2008-12-16 | 2010-07-01 | Onconova Therapeutics, Inc. | Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents |
US20130288985A1 (en) * | 2010-07-15 | 2013-10-31 | The Schepens Eye Research Institute Inc. | Compositions and methods of treatment of corneal endothelium disorders |
WO2014179568A2 (en) * | 2013-05-02 | 2014-11-06 | Odin Biotech | Two-layer ocular implant |
EP3919052A4 (en) * | 2019-01-09 | 2022-10-05 | Fuso Pharmaceutical Industries, Ltd. | PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR THE TREATMENT OF RETINAR DISEASES |
CN112716938A (zh) * | 2021-02-25 | 2021-04-30 | 新疆医科大学 | 鞣花酸在制备缓解眼组织病变的药物中的用途 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456757A (en) * | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
JP3193301B2 (ja) * | 1995-09-14 | 2001-07-30 | 麒麟麦酒株式会社 | 生理活性タンパク質p160 |
US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
US5681854A (en) * | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
ATE289815T1 (de) * | 1995-12-21 | 2005-03-15 | Alcon Lab Inc | Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie |
AU1557497A (en) * | 1996-02-02 | 1997-08-22 | Nippon Shinyaku Co. Ltd. | Isoquinoline derivatives and drugs |
US6586425B2 (en) * | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
DK0956865T4 (da) * | 1996-08-12 | 2010-11-22 | Mitsubishi Tanabe Pharma Corp | Medikamenter omfattende Rho-kinaseinhibitor |
US5759787A (en) * | 1996-08-26 | 1998-06-02 | Tularik Inc. | Kinase assay |
US6573044B1 (en) * | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
US6441033B1 (en) * | 1997-12-22 | 2002-08-27 | Alcon Manufacturing, Ltd. | 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists |
US5958946A (en) * | 1998-01-20 | 1999-09-28 | Styczynski; Peter | Modulation of hair growth |
US6274338B1 (en) * | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
US20010041174A1 (en) * | 1998-11-24 | 2001-11-15 | Najam Sharif | Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases |
US6020383A (en) * | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
US7261881B1 (en) * | 1999-05-20 | 2007-08-28 | Yale University | Modulation of angiogenesis and wound healing |
US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
US6812248B2 (en) * | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
GB0030727D0 (en) * | 2000-12-15 | 2001-01-31 | Lumitech Uk Ltd | Methods and kits for detecting kinase activity |
US6756063B2 (en) * | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
US6884816B2 (en) * | 2001-08-31 | 2005-04-26 | Alcon, Inc. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
TW201041580A (en) * | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
US7199122B2 (en) * | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
WO2003033662A2 (en) * | 2001-10-16 | 2003-04-24 | Atherogenics, Inc. | Protection against oxidative stress and inflammation by a cytoprotective response element |
EP1474158B1 (en) * | 2001-12-18 | 2009-10-14 | Brassica Foundation for Chemoprotection Research, Inc. | Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase ii detoxification enzymes |
US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
US6747025B1 (en) * | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
-
2004
- 2004-12-17 CA CA002548146A patent/CA2548146A1/en not_active Abandoned
- 2004-12-17 US US11/016,116 patent/US20050137147A1/en not_active Abandoned
- 2004-12-17 EP EP04814710A patent/EP1696926A1/en not_active Ceased
- 2004-12-17 MX MXPA06006862A patent/MXPA06006862A/es not_active Application Discontinuation
- 2004-12-17 BR BRPI0417996-0A patent/BRPI0417996A/pt not_active IP Right Cessation
- 2004-12-17 WO PCT/US2004/042562 patent/WO2005063249A1/en active Application Filing
- 2004-12-17 ZA ZA200605378A patent/ZA200605378B/xx unknown
- 2004-12-17 JP JP2006545506A patent/JP2007515422A/ja active Pending
- 2004-12-17 AU AU2004308911A patent/AU2004308911B2/en not_active Ceased
-
2010
- 2010-03-02 US US12/715,853 patent/US20100204244A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2548146A1 (en) | 2005-07-14 |
EP1696926A1 (en) | 2006-09-06 |
JP2007515422A (ja) | 2007-06-14 |
US20100204244A1 (en) | 2010-08-12 |
AU2004308911A1 (en) | 2005-07-14 |
US20050137147A1 (en) | 2005-06-23 |
WO2005063249A1 (en) | 2005-07-14 |
ZA200605378B (en) | 2008-01-30 |
MXPA06006862A (es) | 2007-01-26 |
AU2004308911B2 (en) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0417987A (pt) | agentes para o tratamento de retinopatia glaucomatosa e de neuropatia óptica | |
BRPI0417996A (pt) | agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular | |
Uda et al. | Induction of the anticarcinogenic marker enzyme, quinone reductase, in murine hepatoma cells in vitro by flavonoids | |
AR049518A1 (es) | Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados | |
BRPI0508540B8 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0510778A (pt) | composição farmacêutica, processo para a preparação da mesma, método para o tratamento de rinite, e, uso de uma composição | |
AR013001A1 (es) | Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina. | |
PA8577101A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
BRPI0418082A (pt) | antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a | |
BR0108175A (pt) | Derivados de piperazina e piperidina para o tratamento ou a prevenção de danos neuronais | |
BR0013010B1 (pt) | Formulação aquosa de cloreto de sódio de moxifloxacina, processo para sua preparação e aplicação da referida formulação, bem como preparado de combinação e aplicação de uma solução aquosa de cloridrato de moxifloxacina | |
ECSP045353A (es) | Derivados de benzoxazinona, su preparación y aplicación como medicamentos | |
BRPI0409398A (pt) | preventivo e/ou remédio para doenças do nervo retinal | |
BRPI0511398A (pt) | composição farmacêutica anidra para o tratamento da psorìase e uso de um agente siliconado | |
BRPI0409884A (pt) | compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
BRPI0509454A (pt) | derivados de 4-amino-5-cianopirimidina | |
BR0316108A (pt) | Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos | |
BRPI0510985A (pt) | derivados de ciclopeptìdeo com atividade contra integrina | |
BR0316775A (pt) | Novos análogos de benzopirano e seu uso para o tratamento de glaucoma | |
BR0313186A (pt) | Agente redutor de colesterol proveniente de fibra alimentar e substâncias redutoras de colesterol | |
UY27733A1 (es) | Derivados de ciclopenteno. | |
BR0010525A (pt) | cido 1-ciclo-hexeno-1-carboxìlico e 1-ciclo-hexeno-1carboxilatos como inibidores de neuraminidase | |
BR0304224A (pt) | Uso de pentraxina longa ptx3 para o tratamento de doenças de tumor mediado por fgf-8 | |
BR0313543A (pt) | 2,3-diidro-isoindol-1-onas com atividade de inibição de mao-b | |
Bancirova | The tea protection against the reactive oxygen species produced via the photodynamic effect induced by daylight |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES. |
|
B08I | Application fees: publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |